Phase 2 N=29 Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer
Bladder Cancer
Primary: Percentage of Patients With Complete Pathologic Response After 3 Cycles of Treatment — 27.3 percentage of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=36 First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma
Urothelial Carcinoma
Primary: Median Overall Survival — 13.9 months
Phase 2 N=2 Adjuvant Proton Therapy or IMRT for the Treatment of Bladder Cancer
Urothelial Carcinoma of the Bladder
Primary: Number of Participants With Adverse Events — 2 Participants
Phase 2 N=15 Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors
Bladder Cancer
Primary: Evaluate the Efficacy for Treatment of Low/Intermediate- Risk Bladder Tumors, Assessing for the Clinical Response of the Marker Lesion — 13 Participants
Phase 2 N=43 BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy
Muscle Invasive Bladder Cancer
Primary: Pathologic Response Rate (PaR) at Time of Radical Cystectomy. PaR is Defined as Absence of Residual MIBC at Cystectomy in the Surgical Specimen (Pathologic Down-staging…
Phase 2 N=28 Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer
Bladder Cancer
Primary: The Number of Participants Experiencing an Unacceptable Level of Toxicity as Defined Below — 9; 6; 2; 4 Participants
Phase 2 N=23 Neoadjuvant Atezolizumab in Localized Bladder Cancer
Carcinoma, Transitional Cell
Primary: Mean log2 (Fold Change of CD3+ T-Cell Count/µm2) Over Time — -0.036; -0.041; 1.516 log2(fold change)
Phase 3 N=82 The Bladder Instillation Comparison Study
Urinary Bladder Neoplasms
Primary: Number of Participants Without Grade ≥ 3 Adverse Event, Graded According to NCI CTCAE Version 4.03 — 15; 14; 20 Participants
Phase 3 N=406 S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer
Bladder Cancer
Primary: Disease Recurrence Rate — 27.86; 40 percentage of patients with recurrence — p=0.01
Phase 2 N=83 Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects
Urothelial Carcinoma · Bladder Cancer
Primary: Phase Ib: Safety of Pembrolizumab in Combination With Gemcitabine-Cisplatin — 0 Participants
Phase 2 N=43 Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma
Urinary Tract Urothelial Carcinoma
Primary: Number of Participants With Complete Response at 3 Months — 26 Participants
Phase 2 N=78 Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer
Metastatic Urothelial Carcinoma
Primary: Number of Participants With Overall Response — 9; 8 Participants
Phase 1 N=18 MK-3475/BCG in High Risk Superficial Bladder Cancer
Bladder Cancer
Primary: Number of Participants With Grade 3, 4, and 5 Treatment Related Adverse Events — 0; 4; 3; 6 Participants
Phase 2 N=60 Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer
Bladder Cancer
Primary: Percentage of Participants With Response Defined as the Absence of Residual Muscle Invasive Cancer in Resected Specimen — 38; 53 Percentage of Participants
Phase 2 N=18 Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy
Stage I Bladder Cancer AJCC v8 · Stage II Bladder Cancer AJCC v8 · Stage III Bladder Cancer AJCC v8
Primary: Toxicity for Safety Monitoring (TOX) — 15 percentage of participants
Phase 2 N=39 Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy
Bladder Cancer
Primary: Percentage of Subjects That Reach Pathological Downstaging (Response) at the Time of Cystectomy — 56 percentage of patients with response
Phase 1 N=9 Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer
Recurrent Bladder Carcinoma · Stage 0a Bladder Urothelial Carcinoma · Stage 0is Bladder Urothelial Carcinoma
Primary: Maximum Tolerated Dose (MTD) — 2 mg/kg Pembrolizumab
Phase 2 N=33 RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder
Bladder Cancer
Primary: Phase I - Dose-limiting Toxicity (DLT) — 0 DLT
Phase 2 N=3 Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer
Non-muscle Invasive Bladder Cancer (NMIBC)
Primary: Phase 1: Dose Limiting Toxicities (DLT) Following Intravesical Administration of ABI-009 — 0; 0; 0; 0 Participants
Phase 2 N=58 S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
Bladder Cancer
Primary: Complete Response Rate at the End of Induction — 46 percentage of participants
Phase 2 N=32 Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG
Bladder Cancer
Primary: Percentage of Participants Without Recurrence (Recurrence-free Survival (RFS)) With Bacillus Calmette-Guerin (BCG) + PANVAC Compared With BCG Alone at 6 and 12 Months…
N/A N=592 S1011 Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer
Bladder Cancer
Primary: 5-year Disease-free Survival (DFS) — 60; 56 percentage of participants — p=0.45
Early Phase 1 N=15 Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer
Transitional Cell Carcinoma of Bladder · Superficial Bladder Cancer
Primary: Safety and Tolerability — 5; 2; 1; 1 Grade 1/2 event count (no grade 3+)
Phase 2 N=29 Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma
Urothelial Carcinoma
Primary: Bladder Tumor Recurrence Rate — 41.37 percentage of subjects
Phase 2 N=17 Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer
Stage II Bladder Cancer AJCC v8 · Stage IIIA Bladder Cancer AJCC v8 · Muscle Invasive Bladder Carcinoma
Primary: Pathologic Complete Response Rate — 9 Participants
Phase 2 N=28 Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment
Urinary Bladder Neoplasms
Primary: Number of Participants With Freedom From Progression of Cancer at 4 Months — 20 Participants
Phase 2 N=28 Bristol Bladder Trial
Infiltrating Bladder Urothelial Carcinoma
Primary: Overall Pathological Response Rate — 57.7 % of participants
Phase 2 N=17 Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
Primary: Number of Participants With Progression-free Survival at 6 Months — 3 Participants
Phase 2 N=20 Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer
Bladder Cancer
Primary: EGFR Activation Signal (AKT2) Expression to Predict Sensitivity to Erlotinib — -0.29; 0.128 fold change
Phase 2 N=39 Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
Distal Urethral Cancer · Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter · Proximal Urethral Cancer
Primary: Objective Response Rate — 56.4 percentage of participants